You don't want to miss this! To permanently access these supporting documents, fill out the short form below. At MaxCyte, we share your passion for the discovery, development, and manufacturing of ...

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Fourth Quarter and Full Year Highlights Total revenue of $8.7 million in the fourth quarter of 2024, TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to ...

a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. Receive News & Ratings for MaxCyte Daily - Enter your email ...

a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. Receive News & Ratings for MaxCyte Daily - Enter your email ...

Stifel lowered the firm’s price target on MaxCyte (MXCT) to $9 from $11 and keeps a Buy rating on the shares. Management’s guidance for 2025 positions core ...

MaxCyte Inc (NASDAQ:MXCT) reported a strong year in 2024 with a return to core revenue growth and strategic improvements in operations. The acquisition of SecureDX is expected to enhance MaxCyte's ...

MaxCyte is providing initial 2025 revenue ... Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy ...